BRAF and melanoma: With either immunotherapy, or targeted treatment, Varaljai and colleagues observed that a decrease in BRAF V600E ctDNA levels preceded radiologic detection of response in 80% of melanoma responders with an average lead-time window of 1.5 months (range, 0.023 to 3.45 months; p = 0.003).